News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
234 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44431)
2016 (38329)
2017 (37187)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (27724)
Month
January (4681)
February (5217)
March (5801)
April (5232)
May (5822)
June (5224)
July (4072)
August (4645)
September (4518)
October (4153)
November (5533)
December (3822)
Day
1 (258)
2 (248)
3 (119)
4 (1)
5 (30)
6 (211)
7 (195)
8 (187)
9 (224)
10 (123)
11 (42)
12 (30)
13 (282)
14 (254)
15 (234)
16 (227)
17 (162)
18 (1)
19 (7)
20 (203)
21 (157)
22 (183)
23 (103)
24 (13)
25 (1)
27 (71)
28 (66)
29 (85)
30 (85)
31 (20)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
27
28
29
30
31
Business
Money on the Move: December 8 – 14
During a season of giving, investors were extra generous to these biotech companies this week.
December 15, 2021
·
3 min read
·
Kate Goodwin
Drug Development
Pfizer’s JAK Inhibitor Xeljanz Racks Up Another FDA Win
The FDA’s approval of Xeljanz is based on Pfizer’s Phase III multicenter, double-blind, placebo-controlled study. Here are more details about the study.
December 15, 2021
·
2 min read
·
Vanessa Doctor, RN
Biotech Bay
J.P. Morgan Goes Virtual as Key Companies Back Out
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
December 15, 2021
·
5 min read
·
Gail Dutton
Genetown
Mythic Therapeutics Scores $103 Million to Make “Safer and Smarter” ADCs
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
December 15, 2021
·
3 min read
·
Alex Keown
FDA
FDA Warns Medtronic About Inadequacies at Diabetes Device Facility
The latest warning letter asks Medtronic to update its systems and procedures in order to deliver safe and high-quality devices to consumers.
December 15, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development
Lilly UC Treatment Holds Edge in Maintenance Study, Setting Up BLA
These results set Lilly up well to submit a Biologics License Application (BLA) in the first half of 2022.
December 15, 2021
·
3 min read
·
Sreetama Dutt
Drug Development
Omicron Surges Across the World While Vaccines Struggle to Contain It
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
December 15, 2021
·
6 min read
·
Mark Terry
Drug Development
Notch Another Win for AbbVie’s Rinvoq, This Time in Psoriatic Arthritis
The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.
December 15, 2021
·
2 min read
·
Alex Keown
Business
It’s Back to the Drawing Board for Generation Bio’s Hemophilia A Program
Generation Bio’s stock plummeted 54% to $6.35 yesterday after it reported in an SEC filing that its hemophilia A therapy data in mice couldn’t be duplicated in non-human primate studies.
December 15, 2021
·
2 min read
·
Mark Terry
Career Advice
How to Answer Some Tricky Interview Questions
It’s no secret that employers ask tricky interview questions. But what do you do if you find yourself fumbling for words to answer these tricky questions?
December 15, 2021
·
4 min read
·
Hannah Harshman
1 of 24
Next